The government today, 19 November 2026, confirmed its plans to modernise the legal definition of gene therapy medicinal products (GTMPs). These proposed changes aim to enable certain synthetic gene therapies and novel genome-editing treatments to be regulated under the UK’s established advanced therapies framework.
The proposals, which received support from 83% of consultation respondents, were published in the government's response to a consultation led by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Department of Health in Northern Ireland. Subject to international notification procedures and parliamentary approval, the changes will amend the Human Medicines Regulations 2012.
These amendments are intended to provide developers with greater certainty regarding the classification of these medicines and the regulatory requirements they must meet. Julian Beach, MHRA Executive Director Operations, stated that the proposals will address a gap in the current definition, offering a clearer route to licensing for certain synthetic gene therapies.
The existing approval process and standards for safety, quality, and efficacy will remain unchanged. Medicines already licensed will not require reclassification.